Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals
about
Pathophysiological Role of Neuroinflammation in Neurodegenerative Diseases and Psychiatric DisordersThe relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associationsUnderstanding cognitive deficits in Alzheimer's disease based on neuroimaging findingsReduced synaptic STIM2 expression and impaired store-operated calcium entry cause destabilization of mature spines in mutant presenilin mice.Neuroprotective pathways: lifestyle activity, brain pathology, and cognition in cognitively normal older adults.Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sampleGene-environment interactions: lifetime cognitive activity, APOE genotype, and β-amyloid burden.Interaction Between Midlife Blood Glucose and APOE Genotype Predicts Later Alzheimer's Disease Pathology.Multi-resolutional shape features via non-Euclidean wavelets: applications to statistical analysis of cortical thickness.Amyloid burden, neuronal function, and cognitive decline in middle-aged adults at risk for Alzheimer's diseaseEarly intervention with an estrogen receptor β-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer's disease.The evolution of preclinical Alzheimer's disease: implications for prevention trials.Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals.Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progressionSpatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer diseaseBrain structure and function as mediators of the effects of amyloid on memory.Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span.Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's PreventionAPOε2 and education in cognitively normal older subjects with high levels of AD pathology at autopsy: findings from the Nun StudySubtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's DiseaseDifferent definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findingsAlzheimer's Biomarkers are Correlated with Brain Connectivity in Older Adults Differentially during Resting and Task States.Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology.Multiple Brain Markers are Linked to Age-Related Variation in Cognition.Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD).Insulin-like growth factor-1 in CNS and cerebrovascular agingMetabolic profiling of Alzheimer's disease brainsAssociations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people.Is amyloid-β harmful to the brain? Insights from human imaging studiesThe pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study.Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.Genetic effect of interleukin-1 beta (C-511T) polymorphism on the structural covariance network and white matter integrity in Alzheimer's disease.Biomarker modeling of Alzheimer's disease.Independent value added by diffusion MRI for prediction of cognitive function in older adultsCortical thickness mediates the effect of β-amyloid on episodic memory.The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives.Alzheimer disease therapy--moving from amyloid-β to tau.Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease.Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status.
P2860
Q26745690-58F29C70-9E1A-4519-A2F1-541CD0747882Q26830467-12047EA4-EA36-4CA0-846F-9AA2E25B65E3Q30666527-5CC6E2BA-85E9-4538-ADBF-9CA309DA7AEDQ33554241-70A0B426-198F-4A71-ADAB-A0A708BB45F3Q33605578-45EC70F9-0541-4815-8064-8503EA9C0D69Q33726122-EB7DC79E-D4C0-4B7F-94C1-D835F0205589Q33770441-6C534939-9C8C-412E-B9C7-091B319C4AEEQ33862866-935F1667-1250-4935-8938-BD73C889F368Q33893124-37E6E847-6AA9-4B80-BFAE-1525C1946E58Q33920450-417BB8BE-949E-40BE-A1AF-E904B9095E6FQ34342779-A794F013-DD40-4F29-8316-65F8C18A71CEQ34849048-6E1EB427-E080-4744-A011-4644B4BFE2A1Q34940642-8DEAC939-8428-42C1-B289-8535A32C30EEQ35106472-C6ACCA58-0C6C-4857-AC18-59603547443FQ35195654-30F3D30D-C9BE-47C3-8E4A-ABC013C4751EQ35211063-29EF91FF-CA69-417D-B40D-9371012B9487Q35598271-551A114D-67BD-4163-B042-EBA2479B3E1AQ35820280-CE994B51-9423-46D1-B1D6-AF9B9EDF1987Q35987278-D529BBD4-9CF6-4EDE-89F7-D75F6C2122C5Q36252707-BF4007AE-414E-4090-A8B9-1FA3D8CF3F93Q36305487-CE66680C-915B-49D3-B646-465770B94659Q36554846-2E15C336-E92E-4C90-8BB9-3A4F1E14070DQ36615483-1094EDC5-A93D-4721-BB3E-C85ED8965F04Q36672521-9F372914-0482-462F-85DF-F9C0CF473376Q36713818-A73C537F-C0A2-432A-8ED5-79A6DFD7AA13Q36973428-4D4818A9-C973-485F-A245-D72533C1F0C0Q37072582-B96DEA2F-23B1-454E-8251-AD1314DDD3E8Q37129672-8DE32909-B7C9-49A5-8BAB-DC6438F7D03FQ37188315-0736E58A-17E7-4418-A412-55F781A2001FQ37251058-360FBEC7-A70D-4055-84E3-9A926E0B6DC6Q37410700-B0B2CC56-746C-4EAC-A4C0-69C32F5B303FQ37520832-01F943D4-880F-409C-87D0-8EA1567E27A4Q37591588-65700F0E-8636-4984-B595-CF7CDA7BB530Q37592824-39F9E604-3CC6-432F-AB31-D3CA11413B2FQ37613574-6F156F3D-A3C7-4B68-8D17-C6CC3D6B7091Q37623176-641DFF79-215D-4718-90FF-172883EE486AQ37656554-5A3F4FB3-20EC-40EB-AA65-EA7E9E3AB9B0Q38161786-8E541DDF-AAC5-4BF8-9D4E-29D4D2177906Q38240609-170E6CE1-9054-4AC5-9750-FC068D3D4722Q38253573-42EA8969-A735-46A9-A88D-BCAC680A7B1E
P2860
Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Alzheimer's disease neurodegen ...... ively normal older individuals
@en
type
label
Alzheimer's disease neurodegen ...... ively normal older individuals
@en
prefLabel
Alzheimer's disease neurodegen ...... ively normal older individuals
@en
P2093
P2860
P921
P1476
Alzheimer's disease neurodegen ...... ively normal older individuals
@en
P2093
Cindee M Madison
Miranka Wirth
Susan M Landau
William J Jagust
P2860
P304
P356
10.1523/JNEUROSCI.4409-12.2013
P407
P577
2013-03-01T00:00:00Z